N. Perualila

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study

Tetsuro Ito, F. Saad, K. Fizazi, 2019, Targeted Oncology.

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

H. Einsele, S. Jagannath, A. Jakubowiak, 2022, Haematologica.

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

J. Wolf, Jedelyn Cabrieto, Nicole Erdmann, 2023, Advances in Therapy.

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

H. Goldschmidt, S. Jagannath, P. Hari, 2021, Cancers.

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

H. Einsele, S. Jagannath, A. Jakubowiak, 2021, Blood.

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

N. Perualila, A. Oliveira-Maia, Siobhán Mulhern-Haughey, 2023, Frontiers in psychiatry.

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry

N. Perualila, S. Barbreau, A. Oliveira-Maia, 2023, Frontiers in psychiatry.